CoChat

Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer

Open access
Locatelli, Marzia A., Aftimos, Philippe, Dees, E. Claire, LoRusso, Patricia M., Pegram, Mark D., Awada, Ahmad, Huang, Bo, Cesari, Rossano, Jiang, Yuqiu, Shaik, M. Naveed, Kern, Kenneth A., Curigliano, Giuseppe · 2017 · Oncotarget
Cited by 91

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

// Marzia A. Locatelli 1 , Philippe Aftimos 2 , E. Claire Dees 3 , Patricia M. LoRusso 4,9 , Mark D. Pegram 5 , Ahmad Awada 2 , Bo Huang 6 , Rossano Cesari 7 , Yuqiu Jiang 8 , M. Naveed Shaik 8 , Kenneth A. Kern 8 and Giuseppe Curigliano 1 1 Division of Experimental Therapeutics, European Institute of Oncology, Milan, Italy 2 Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium 3 Department of Hematology and Oncology, University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA 4 Medical Oncology, Karmanos Cancer Institute, Detroit, MI, USA 5 Breast Cancer Research Program, Stanford Cancer Institute, Stanford, CA, USA 6 Pfizer Oncology, Groton, CT, USA 7 Pfizer Oncology, Milan, Italy 8 Pfizer Oncology, San Diego, CA, USA 9 Yale Cancer Center, New Haven, CT, USA Correspondence to: Giuseppe Curigliano, email: // Keywords : breast cancer, triple-negative, PF-03084014, gamma secretase, NOTCH signaling Received : July 25, 2016 Accepted : November 22, 2016 Published : November 30, 2016 Abstract Background: The NOTCH signaling pathway may be involved in the survival of stem cell-like tumor-initiating cells and contribute to tumor growth. In this phase Ib, open-label, multicenter study (NCT01876251), we evaluated PF-03084014, a selective gamma-secretase inhibitor in patients with advanced triple-negative breast cancer. Methods: The dose-finding part was based on a 2×3 matrix design using the modified toxicity probability interval method. Oral PF-03084014 was administered twice daily continuously in combination with intravenous docetaxel given on day 1 of each 21-day cycle. Primary endpoint was first-cycle dose-limiting toxicity (DLT) for the dose-finding part and 6-month progression-free survival (PFS) for the expansion cohort treated at the maximum tolerated dose (MTD). Secondary endpoints included safety, objective response, and pharmacokinetics of the combination. Results and Conclusions: The MTD was estimated to be PF-03084014 100 mg twice daily / docetaxel 75 mg/m 2 . At this dose level, combination treatment was generally well tolerated (one DLT, grade 3 diarrhea, among eight DLT-evaluable patients). The most common all-grade, treatment-related adverse events reported in all patients ( N = 29) were neutropenia (90%), fatigue (79%), nausea (72%), leukopenia (69%), diarrhea (59%), alopecia (55%), anemia (55%), and vomiting (48%). No effect was observed on the pharmacokinetics of docetaxel when administered in combination with PF-03084014. Four (16%) of 25 response-evaluable patients achieved a confirmed partial response; nine (36%) patients had stable disease, including five patients with unconfirmed partial response. In the expansion cohort, median PFS was 4.1 (95% CI 1.3-8.1) months (6-month PFS rate 17.1% [95% CI 0.8-52.6%]).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.13727

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 91

Metadata

Authors
Locatelli, M. A., Aftimos, P., Dees, E. C., LoRusso, P. M., Pegram, M. D., Awada, A., Huang, B., Cesari, R., Jiang, Y., Shaik, M. N., Kern, K. A., & Curigliano, G.
Venue
Oncotarget
Published
2016-11-30
Volume
8
Issue
2
Pages
2320-2328
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2559471841
Cited by
91
References
3
FWCI
3.40
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.